All rights reserved https://phaidrabg.bg.ac.rs/o:30918 Serbian Biochemical Society Twelfth Conference, International scientific meeting "Biochemistry in Biotechnology" 21-23.09.2023. Belgrade, Serbia. Proceedings. p. 79 (M34) 12 2023 Popović, Kosta J. Popović, Dušica J. Miljković, Dejan Lalošević, Dušan Čapo, Ivan Poša, Mihalj Popović, Jovan K. Dolićanin, Zana Abstract: The NF-kB activity in cancer cells promotes tumor growth by stimulation of cell proliferation, neoangiogenesis and by inhibition of apoptosis and ROS activity. Anticancer combinations of two repurposed drugs: metformin with 2-Deoxy-D-glucose, deoxycholic acid, caffeine, itraconazole or disulfiram (<50% LD50, equivalent to usual human dose) mechanism of action was investigated by rescuing treated BHK-21/C13 fibrosarcoma growth in hamsters with ROS inhibitor nitroglycerin and NF-kB stimulator mebendazole. 19 days after inoculation, anticancer effects were assessed by biophysical measurements of fibrosarcoma growth and immunohistochemical markers of tumor proliferation (Ki-67, PCNA), neoangiogenesis (CD34, CD31), glucose metabolism (GLUT1), NO metabolism (iNOS) and apoptosis (COX4, Cytochrome C). The combinations have shown significant antitumor effects (P<0.05) which were inhibited partly by addition of ROS inhibitor nitroglycerin and completely by NF-kB stimulator mebendazole. Results indicate NF-kB key role in anticancer action of investigated drug combinations of non-oncological drugs and their potential to be used in oncology. application/pdf 258662 bytes eng info:eu-repo/semantics/conferenceProceedings Twelfth Conference, International scientific meeting "Biochemistry in Biotechnology" 21-23.09.2023. Belgrade, Serbia. ROS and NF-kB role in repurposed drugs treatment of hamster fibrosarcoma